CES2 Expression in Pancreatic Adenocarcinoma Is Predictive of Response to Irinotecan and Is Associated With Type 2 Diabetes
Author(s) -
Michela Capello,
Johannes F. Fahrmann,
Mayrim V. Rios Perez,
Jody V. Vykoukal,
Ehsan Irajizad,
S. C. Tripathi,
David Roife,
Leonidas E. Bantis,
Ya’an Kang,
Deepali L. Kundnani,
Hanwen Xu,
Laura R. Prakash,
James P. Long,
Hiroyuki Katayama,
Alia Fleury,
Sammy FerriBorgogno,
Dodge L. Baluya,
Jennifer B. Dennison,
Clemente Aguilar-Bonavides,
Julian P Casabar,
Müge Çeliktaş,
KimAnh Do,
Oliver Fiehn,
Anirban Maitra,
Huamin Wang,
Ziding Feng,
Paul J. Chiao,
Matthew H. G. Katz,
Jason B. Fleming,
Samir Hanash
Publication year - 2020
Publication title -
jco precision oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.405
H-Index - 22
ISSN - 2473-4284
DOI - 10.1200/po.19.00330
Subject(s) - folfirinox , irinotecan , medicine , pancreatic cancer , cancer research , oncology , gemcitabine , camptothecin , cancer , biology , biochemistry , colorectal cancer
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom